GE Healthcare and Takeda Pharmaceutical have entered into an alliance agreement for research and development in the field of hepatic fibrosis, a key factor in the diagnosis and treatment of liver diseases.
GE Healthcare will provide Takeda with its diagnostic imaging technology for use to generate a liver stiffness map as part of the research and development work Takeda is conducting on liver diseases.
By optimizing the strengths of both companies in the alliance, the collaborative effort aims to help develop therapeutic drugs as well as new diagnostic technologies for liver diseases.
Details about the terms of the agreement including financial stipulations are not being disclosed.
The contract pertains to an alliance involving diagnoses in the development of therapeutic drugs for liver disease.